New drug cocktail targets Hard-to-Treat lung cancer

NCT ID NCT07639242

Not yet recruiting Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This phase 2 trial tests a combination of two drugs, olomorasib and pembrolizumab, as a first treatment for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and a PD-L1 score between 1% and 49%. The main goal is to see how long patients live without their cancer getting worse. About 60 participants will receive the drugs, and researchers will also track tumor shrinkage, side effects, and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olomorasib and pembrolizumab
What this could lead to: If it works, this combination could offer a new first-line treatment option for people with a specific type of advanced lung cancer, potentially helping them live longer without their cancer worsening.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED NSCLC LUNG CANCER LUNG CANCER (NSCLC) METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.